BMS-986094 (INX-08189) is a prodrug of a guanosine nucleotide analogue which was developed to treat hepatitis C virus but was discontinued during clinical trials due to cardiotoxic effects.
In this poster, we focus on:
the mechanism of BMS-986094 cardiotoxicity
the impact of chronic dosing over multiple time points
evaluation of data from an MEA platform, a cardiac mitochondrial protein biogenesis assay, a calcium flux assay and a cardiac cytotoxicity assay
Read our poster to learn more about our research!
Sounds interesting? Enter your details below to continue reading…
Join our community
Discover the exclusive benefits on offer if you join our community.